#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chronic graft versus host disease in intestine Univentricular heart Hereditary angioedema Non-renal cell carcinoma of kidney Exudative retinopathy Anti-neutrophil cytoplasmic antibody positive vasculitis Autoimmune demyelinating disease Soft tissue necrosis Oropharyngeal cancer recurrent Hyperinsulinaemic hypoglycaemia Piriformis syndrome Angiosarcoma Alpha-1 antitrypsin deficiency High-grade B-cell lymphoma Diffuse large B-cell lymphoma More trials…

    Learn about Rare Diseases

    Pleural mesothelioma malignant – Life with Disease Osteosarcoma recurrent – Diagnostics Idiopathic pulmonary fibrosis – Basic Information Pleomorphic leiomyosarcoma – Trials in Disease Systemic sclerosis pulmonary – Treatment Synovial sarcoma – Trials in Disease Splenic marginal zone lymphoma – Life with Disease Haemophagocytic lymphohistiocytosis – Diagnostics Lennox-Gastaut syndrome Turner’s syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Copanlisib Dihydrochloride Nadroparin Calcium Isatuximab [18F]CPFPX VGA039 Amifostine Thiol Fluconazole Deutivacaftor Elamipretide Trihydrochloride Orismilast Topotecan Hydrochloride Amniotic Membrane, Human Phenylalanine Litenimod Sodium Benzylpenicillin Riliprubart Linvoseltamab Atomoxetine Thiamine Nitrate Bp Argon More therapies…

    Learn about Your Condition

    Eosinophilic oesophagitis Astrocytoma malignant Notalgia paraesthetica Acute lymphocytic leukaemia Chronic hepatic failure Procedural anxiety Intermittent claudication Hypertriglyceridaemia Hypogonadism male Glioblastoma Nervous system disorder Thrombosis prophylaxis Post-traumatic stress disorder Aortic valve disease Hyponatraemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

HER2 positive breast cancer

  • Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    • Trastuzumab Emtansine
    Belgium Czechia Denmark France Germany Greece +7

  • Study on Trastuzumab and Pertuzumab for Patients with HER2-Positive Breast Cancer Using a Response-Adapted Strategy

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Letrozole
    • Tamoxifen Citrate
    • Pertuzumab
    France Germany Italy Portugal Spain

  • Study on Time Savings with Subcutaneous Pertuzumab and Trastuzumab for Patients with HER2-Positive Early Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive breast cancer
    • HER2 positive breast cancer
    Investigated Drugs:
    • Pertuzumab
    • Trastuzumab
    Spain

  • Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Giredestrant
    • Anastrozole
    • Anhydrous Docetaxel
    Belgium France Germany Hungary Italy Poland +2

  • Study of Trastuzumab Deruxtecan for Patients with HER2-Positive Metastatic Breast Cancer Resistant to Trastuzumab, Pertuzumab, and Taxane Treatment

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • HER2 positive breast cancer
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    Spain

  • Study of Alpelisib, Trastuzumab, and Fulvestrant for Patients with PIK3CA Mutated HER2+ Advanced Breast Cancer Previously Treated with Trastuzumab

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • HER2 positive breast cancer
    Investigated Drugs:
    • Alpelisib
    Spain
Previous Page
1 … 5 6 7

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!